|
The
company said sales of its diabetes drug, Januvia, fell 12
percent to $1.45 billion in the fourth quarter, while sales of
its arthritis drug, Remicade, fell 29 percent to $396 million.
Merck's shares were down 2.2 percent at $49.28 in premarket
trading on Wednesday.
The company forecast 2016 revenue of $38.7 billion-$40.2
billion, the top end of which was in line with the average
analyst estimate.
The U.S. drugmaker's total revenue fell 2.5 percent to $10.22
billion. Analysts were estimating revenue of $10.35 billion,
according to Thomson Reuters I/B/E/S.
The company said a strong dollar had a 7 percent negative impact
on its total revenue.
Net income attributable to the company fell to $976 million, or
35 cents per share, for the fourth quarter ended Dec. 31 from
$7.32 billion, or $2.54 per share, from a year earlier.
Excluding special items, the company earned 93 cents per share,
beating the average analyst estimate of 91 cents per share.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Don
Sebastian and Anil D'Silva)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
